Skip to main content
. Author manuscript; available in PMC: 2018 May 1.
Published in final edited form as: Mol Cancer Res. 2017 May;15(5):521–531. doi: 10.1158/1541-7786.MCR-16-0315

Figure 2.

Figure 2

High-dose androgens suppress BIRC5 levels and increase YM155 mediated DNA-damage. A) Western blots for BIRC5 (survivin), γH2AX, Beclin, ATG5, Caspase3, and PARP1 on LNCaP treated for 24 hrs with 0.5 or 1 uM YM155 with and without a 48 hour pre-incubation with 10nM R1881. B) LNCaP viability (CellTiter-Glo) in response to YM155 with or without 2.5 nM Testosterone (T). (Error = standard deviation) (n=4) C) YM155 IC50 values of LNCaP pre-incubated 24hrs with 10nM R1881 or vehicle control then exposed to a dose range of YM155 for 24, 48, and 72 hrs (Error = 95% confidence interval, n=4).